Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556872 | 0.84 | NR1H2 (0.37) | HTR2AHTR2CHTR2BHCRTR2 | |
| SCHEMBL556475 | 0.81 | HTR2A (0.44) | KDM1AHTR2AHTR2CHTR2BADAMTS5 | |
| SCHEMBL27896146 | 0.75 | HTR2A (0.49) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL556599 | 0.73 | CYP1A2 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL2479416 | 0.72 | KDM1A (0.40) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL556873 | 0.71 | ADAMTS5 (0.33) | KDM1AHTR2AHTR2CHTR2BADAMTS5 | |
| SCHEMBL556462 | 0.70 | PDE4B (0.43) | HTR2AHTR2CHTR2BGPR88 | |
| SCHEMBL6902319 | 0.69 | CCR5 (0.42) | KDM1A | |
| SCHEMBL1713447 | 0.69 | CCR5 (0.42) | KDM1A | |
| SCHEMBL3646250 | 0.69 | CCR5 (0.42) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM1A 2899/4885HTR2A 3006/4885HTR2C 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.